000 01349 a2200349 4500
005 20250516231034.0
264 0 _c20150511
008 201505s 0 0 eng d
022 _a1940-6029
024 7 _a10.1007/978-1-4939-0956-8_10
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aLymperopoulos, Anastasios
245 0 0 _aPharmacogenomics of heart failure.
_h[electronic resource]
260 _bMethods in molecular biology (Clifton, N.J.)
_c2014
300 _a245-57 p.
_bdigital
500 _aPublication Type: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
650 0 4 _aAdrenergic beta-Antagonists
_xtherapeutic use
650 0 4 _aAngiotensin-Converting Enzyme Inhibitors
_xtherapeutic use
650 0 4 _aG-Protein-Coupled Receptor Kinase 5
_xgenetics
650 0 4 _aGenetic Variation
650 0 4 _aGenotype
650 0 4 _aHeart Failure
_xdrug therapy
650 0 4 _aHumans
650 0 4 _aPeptidyl-Dipeptidase A
_xgenetics
650 0 4 _aPharmacogenetics
650 0 4 _aReceptors, Adrenergic, alpha
_xgenetics
650 0 4 _aReceptors, Adrenergic, beta
_xgenetics
650 0 4 _aTreatment Outcome
700 1 _aFrench, Faren
773 0 _tMethods in molecular biology (Clifton, N.J.)
_gvol. 1175
_gp. 245-57
856 4 0 _uhttps://doi.org/10.1007/978-1-4939-0956-8_10
_zAvailable from publisher's website
999 _c24124292
_d24124292